Fort Myers-based cancer testing and research lab NeoGenomics expects to report double-digit revenue growth for 2025. However, ...

NeoGenomics appointed Abhishek Jain to the role of chief financial officer, succeeding Jeff Sherman, who is set to retire from the position in March.

Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 ...

(NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the ...

Lab is located in same building as PPD® Laboratories’ Central Lab and will support Asia-Pacific oncology trials Fully integrated with PPD’s CRO capabilities, PPD Laboratories offers bioanalytical, ...

FT. MYERS, Fla., Oct. 23, 2018 (GLOBE NEWSWIRE) — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive ...

This time it's going to China. The Fort Myers-based laboratory — specializing in genetic testing for cancer — has announced plans to grow its global footprint with the addition of a research lab in ...

Despite experiencing a double-digit decline in test volumes, the cancer genetics lab hasn't furloughed employees. It has even retooled labs to process COVID-19 swab and blood tests. The slowdown is ...

FORT MYERS, FL / ACCESSWIRE / October 13, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced plans to open a ...